Autres langues Haemonetics Corporation

Actions

HAE

US4050241003

Marché Fermé - Nyse Autres places de cotation 22:00:02 26/04/2024			Varia. 5j.	Varia. 1 janv.
90,99 ^USD	+3,80 %		+12,00 %	+6,41 %

04/04	Haemonetics obtient l'autorisation de la FDA pour la nouvelle cartouche TEG 6s Global Hemostasis-HN	MT
04/04	Haemonetics Corporation reçoit l'autorisation de la FDA pour la nouvelle cartouche TEG® ? 6s Global Hemostasis - HN Cartridge	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2024 Results: May 9, 2024	10/04
Haemonetics Receives FDA Clearance for New TEG 6s Global Hemostasis - HN Cartridge	05/04
Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge	04/04
Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge	04/04
Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge	04/04
Haemonetics Corporation Completes Acquisition of Attune Medical	01/04
Haemonetics Corporation completed the acquisition of Advanced Cooling Therapy, Inc.	01/04
Haemonetics to Acquire Attune Medical for $160 Million	05/03
Haemonetics Announces Definitive Agreement to Acquire Attune Medical	05/03
Haemonetics to Present at Raymond James 45th Annual Institutional Investors Conference	21/02
Haemonetics to Present at Citi's 2024 Unplugged Medtech and Life Sciences Access Day	21/02
Haemonetics Q3 Adjusted Earnings, Revenue Increase; Shares Rise	08/02
North American Morning Briefing : S&P 500 to Open -2-	08/02
Haemonetics: Fiscal Q3 Earnings Snapshot	08/02
Haemonetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 30, 2023	08/02
Haemonetics Corporation Updates Revenue Guidance for the Fiscal Year 2024	08/02
Haemonetics 3rd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website	08/02
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2024 Results: February 8, 2024	11/01
Haemonetics Completes $255 Million Acquisition of OpSens	12/12
OpSens Brief: NYSE's Haemonetics Completed Acquisition	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Haemonetics Corporation

Actions

HAE

US4050241003

Autres langues

Filtres